Abstract:Abstract Background Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics. Significant intra- and inter-tumor heterogeneity and inadequate delivery of therapeutics across blood–brain barrier continue to be significant impediments towards developing therapies which can significantly enhance survival. We hypothesize that microRNAs have the potential to serve as effective therapeutics for glioblastoma as they modulate the activity of multiple signaling pathways, and hence can counteract heterogeneity if successfully delivered. Methods Using a computational approach, we identified microRNA-34a as a microRNA that maximally reduces the activation status of the three core signaling networks (the receptor tyrosine kinase, p53 and Rb networks) that have been found to be deregulated in most glioblastoma tumors. Glioblastoma cultures were transfected with microRNA-34a or control microRNA to assess biological function and therapeutic potential in vitro. Nanocells were derived from genetically modified bacteria and loaded with microRNA-34a for intravenous administration to orthotopic patient-derived glioblastoma xenografts in mice. Results Overexpression of microRNA-34a strongly reduced the activation status of the three core signaling networks. microRNA-34a transfection also inhibited the survival of multiple established glioblastoma cell lines, as well as primary patient-derived xenograft cultures representing the proneural, mesenchymal and classical subtypes. Transfection of microRNA-34a enhanced temozolomide (TMZ) response in in vitro cultures of glioblastoma cells with primary TMZ sensitivity, primary TMZ resistance and acquired TMZ resistance. Mechanistically, microRNA-34a downregulated multiple therapeutic resistance genes which are associated with worse survival in glioblastoma patients and are enriched in specific tumor spatial compartments. Importantly, intravenous administration of nanocells carrying miR-34a and targeted to epidermal growth factor receptor (EGFR) strongly enhanced TMZ sensitivity in an orthotopic patient-derived xenograft mouse model of glioblastoma. Conclusions Targeted bacterially-derived nanocells are an effective vehicle for the delivery of microRNA-34a to glioblastoma tumors. microRNA-34a inhibits survival and strongly sensitizes a wide range of glioblastoma cell cultures to TMZ, suggesting that combination therapy of TMZ with microRNA-34a loaded nanocells may serve as a novel therapeutic approach for the treatment of glioblastoma tumors.

Exploring molecular mechanism of novel liposomal nanoparticles application in glioma

[Down-Regulation of Lncrna TTTY15 Targeting Mir-4500 to Inhibit the Biological Characteristics of A172 Glioma Cells].

Molecular Mechanism of Inhibition of Glioma by Targeting Autophagy Microtubule-Associated Protein 1A/1B-Light Chain 3 Family via miR-16 with Novel Liposome Nanoparticles

MicroRNA-509-3p Inhibits Cell Proliferation and Invasion Via Downregulation of X-linked Inhibitor of Apoptosis in Glioma.

Microrna-149 Targets Caspase-2 in Glioma Progression

Microrna-221 Targeting Pi3-K/Akt Signaling Axis Induces Cell Proliferation and Bcnu Resistance in Human Glioblastoma

Inhibiting the expression of anti-apoptotic genes BCL2L1 and MCL1, and apoptosis induction in glioblastoma cells by microRNA-342

Effect of Nanoparticles of DOX and miR-125b on DNA Damage Repair in Glioma U251 Cells and Underlying Mechanisms

Mir-494-3p Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by PTEN/AKT Signaling in Human Glioblastoma Cells

Tailored Lipoprotein‐Like miRNA Delivery Nanostructure Suppresses Glioma Stemness and Drug Resistance through Receptor‐Stimulated Macropinocytosis

Brain targeted biomimetic siRNA nanoparticles for drug resistance glioblastoma treatment

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma

Study of MiR-451 in the Treatment of Human Gliomas through Regulating the AMPK Pathway Mediated by Bone Mesenchymal Stem Cells

miRNA Delivery: Tailored Lipoprotein‐Like miRNA Delivery Nanostructure Suppresses Glioma Stemness and Drug Resistance through Receptor‐Stimulated Macropinocytosis (Adv. Sci. 5/2020)

Mir-508-5p Inhibits the Progression of Glioma by Targeting Glycoprotein Non-Metastatic Melanoma B

In Silico Analysis Identified Mirna-Based Therapeutic Agents Against Glioblastoma Multiforme

Role of short hairpin RNA targeting survivin in apoptosis and G2/M cell cycle arrest in glioma cell line U251

Microrna-149 Inhibits Proliferation and Invasion of Glioma Cells Via Blockade of Akt1 Signaling

MicroRNA-16 Inhibits Glioma Cell Growth and Invasion Through Suppression of BCL2 and the Nuclear Factor-Κb1/mmp9 Signaling Pathway.

Combination of microRNA and suicide gene for targeting Glioblastoma: Inducing apoptosis and significantly suppressing tumor growth in vivo

miR-92b-3p Regulates Cell Progression and Drug Resistance through Upregulation of CXCL5 in Glioma